Dalfampridine Associated Serious Adverse Events: An Analysis of Data from the Food and Drug Administration’s Adverse Event Reporting System

Nursing and Health Professions

• Fampridine 100%
• Food and Drug Administration 100%
• Multiple Sclerosis 37%
• Dizziness 25%
• Balance Disorder 12%
• Weakness 12%
• Potassium Channel Blocking Agent 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• 4-Aminopyridine 100%
• Multiple Sclerosis 42%
• Side Effect 28%
• FDA Adverse Event Reporting System 14%
• Strangury 14%